title: Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison.
abstract: Pitavastatin (CAS 147526-32-7, NK-104), the first totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor discovered in Japan, was examined. Pitavastatin significantly decreased the serum levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) at doses of 1 mg/day or more, and significant dose-dependence of the effect of this drug was observed within the dose range from 1 mg/day to 4 mg/day. It also significantly decreased the serum levels of triglycerides (TG) within this dose range. There was no dose-dependence of the incidence of adverse reactions to pitavastatin.
authors.affiliation: Second Department of Internal Medicine, School of Medicine, Chiba University, Chiba, Japan. yasushi@intmed02.m.chiba-u.ac.jp
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Saito
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Yamada
authors.forename: Tamio
authors.initials: T
authors.lastname: Teramoto
authors.forename: Hiroshige
authors.initials: H
authors.lastname: Itakura
authors.forename: Yoshiya
authors.initials: Y
authors.lastname: Hata
authors.forename: Noriaki
authors.initials: N
authors.lastname: Nakaya
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Mabuchi
authors.forename: Motoo
authors.initials: M
authors.lastname: Tushima
authors.forename: Jun
authors.initials: J
authors.lastname: Sasaki
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Goto
authors.forename: Nobuya
authors.initials: N
authors.lastname: Ogawa
mesh_terms: D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D011804:Quinolines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D011804:Quinolines; D014280:Triglycerides; D002784:Cholesterol; C108475:pitavastatin